Iterum Therapeutics plc (ITRMF) Non-Current Debt (2018 - 2023)

Iterum Therapeutics' Non-Current Debt history runs 6 years deep, the most recent figure standing at $11.5 million for Q4 2023.

• In Q4 2023, Non-Current Debt rose 13.46% year-over-year to $11.5 million; the TTM figure through Dec 2023 stood at $11.5 million (up 13.46% YoY), while the FY2023 annual figure was $11.5 million, up 13.46% from the prior year.
• Non-Current Debt for Q4 2023 stood at $11.5 million, down from $12.5 million in the prior quarter.
• The five-year high for Non-Current Debt was $22.5 million in Q4 2020, with the low at $5.3 million in Q2 2021.
• The 5-year median for Non-Current Debt is $10.4 million (2019), against an average of $11.5 million.
• The sharpest annual moves came in 2020 and 2021: Non-Current Debt surged 194.58% in 2020, then plunged 74.49% in 2021.
• Iterum Therapeutics' Non-Current Debt stood at $7.6 million in 2019, then soared by 194.58% to $22.5 million in 2020, then plunged by 69.15% to $6.9 million in 2021, then surged by 45.66% to $10.1 million in 2022, then advanced by 13.46% to $11.5 million in 2023.
• Business Quant data shows ITRMF's Non-Current Debt at $11.5 million in Q4 2023, $12.5 million in Q3 2023, and $11.7 million in Q2 2023.